Teaching methods include lecture/didactic, Q&A with faculty, panel discussion, case presentation and audience response system.

This year's keynote speaker is Dr. Stephen Hanauer, an Internationally recognized expert on the treatment of inflammatory bowel disease (IBD) and advisor on the development of multiple leading IBD drugs. He is a board-certified internist and gastroenterologist and prior to joining Northwestern University’s Feinberg School of Medicine as the Clifford Joseph Barborka Professor of Medicine and Medical Director of the Digestive Health Center at Northwestern University's Feinberg School of Medicine; Dr. Hanauer was the Joseph B. Kirsner Professor and Chief of Gastroenterology, Hepatology and Nutrition at the University of Chicago. Dr. Hanauer is a Master and past President of the American College of Gastroenterology (ACG) and the former Chair of the American Gastroenterological Association's Inflammation, Immunology, and IBD Section as well as the Clinical Practice chair. He is also a prior member of the Gastroenterology Specialty Board of the American Board of Internal Medicine and is a member and former-Chairman of the International Organization for Inflammatory Bowel Disease. Dr. Hanauer has expertise in designing and leading clinical studies for IBD related therapies and has acted as a clinical investigator and/or advisor to pharmaceutical companies in the development of many leading IBD therapies. Dr. Hanauer has authored over 570 peer-reviewed journal articles and numerous books and book chapters, abstracts, monographs, and editorials.

TARGET AUDIENCE

Medical Professionals in:

• Gastroenterology
• General Practice
• Hospitalist
• Internal Medicine
• OBGYN / Obstetrics & Gynecology
• Radiology
• Colorectal Surgery
• General Surgery

LEARNING OBJECTIVES

At the conclusion of this activity, participants should be able to:

• Analyze and evaluate the latest evidence and identify the strengths and limitations of head-to-head clinical trials in IBD
• Learn how to apply the most recent evidence regarding mucosal healing, neoplasia surveillance and treatment optimization including combination advanced therapy for IBD in clinical practice
• Learn about new medical treatment options in IBD and how they may affect the therapeutic landscape
• Understand the role of the multi-disciplinary team including colorectal surgeon, gastroenterologist, nutritionist, pharmacist and psychologist for the management of patients with IBD
• Review the evidence supporting the efficacy and safety of biosimilars in IBD

This event is powered by Well-Assembled Meetings.

To review the agenda, view the accreditation statement, and to register for the event, click the REGISTER NOW button below